Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
RiboNova, Inc. logo — Focused on Mitochondrial Disease & other serious rare diseas...

RiboNova, Inc.

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.

Founded 2011 United States Wynnewood, United States 7 employees Venture round Total: $25.00K Biotechnology, Pharmaceutical

General Information

Company Name RiboNova, Inc.
Founded Year 2011
Location United States Wynnewood, United States
Employees 7
Industries Biotechnology, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with RiboNova, Inc.. To contact RiboNova, Inc., visit ribonova.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RiboNova, Inc. compare?

A PDF of RiboNova, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RiboNova, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RiboNova, Inc.

RiboNova, Inc. is a biopharmaceutical company founded in 2011, with a primary focus on developing treatments for mitochondrial disease and other serious rare diseases. The company's flagship asset, R007, is a Phase-2 ready small molecule drug designed to address all forms of genetically-confirmed mitochondrial disease. Additionally, RiboNova has a tRNA discovery program that targets defective transfer RNAs, offering potential treatment options for a range of human diseases. The burden of mitochondrial disease is severe, with an estimated 75,000 people affected in the US, and high morbidity and mortality rates, especially in children. Despite the significant impact on patients and the healthcare system, there are currently no FDA-approved drugs for mitochondrial disease. RiboNova's approach is notable for its innovative focus on targeting the underlying genetic causes of the disease, using DNA sequencing and a proprietary drug discovery platform to develop precision medicines. One of the company's key strengths lies in its commitment to addressing the unmet needs of patients suffering from mitochondrial diseases. RiboNova's strategic positioning within the Lankenau Institute for Medical Research near Philadelphia also provides access to valuable resources and expertise in the biopharmaceutical field. With a $25.00K Venture Round investment in March 2019, the company is positioned for further growth and potential breakthroughs in the treatment of mitochondrial and other rare diseases.

Business keywords: biopharmaceutical company, rare diseases, mitochondrial disease, treatment, drug discovery, precision medicine, tRNA, genetic diagnosis, DNA sequencing, ribonucleic acid, clinical biomarkers, therapeutic targets, translational medicine, Phase-2 ready drug

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $25.00K -
01 Mar 2019
Seed Round Undisclosed 1
BioAdvance
BioAdvance
23 Feb 2016

RiboNova, Inc. Alternatives & Competitors

View All Alternatives
RiboNova, Inc. vs
MDI Therapeutics, Inc.
MDI Therapeutics, Inc. United States

Developing novel serpin-based therapies

Series A
5 employees
Biotechnology, Health and Wellness
RiboNova, Inc. vs
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. United States

We develop precision medicines for rare and refractory epilepsy.

3 employees
Biopharma, Biotechnology
RiboNova, Inc. vs
Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. United States

A clinical-stage drug platform company focused on treating neuroinflammation.

Private Equity
6 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About RiboNova, Inc.

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.
RiboNova, Inc. was founded in 2011.
RiboNova, Inc. is headquartered in Wynnewood, United States.
RiboNova, Inc. operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical company, rare diseases, mitochondrial disease and treatment.
RiboNova, Inc. has approximately 7 employees.
RiboNova, Inc. has completed 2 funding rounds, raising a total of $25.00K. The latest funding stage is Venture round.
Top alternatives and competitors to RiboNova, Inc. include MDI Therapeutics, Inc., Epygenix Therapeutics, Inc., Jupiter Neurosciences, Inc., Cullgen Inc., Dynacure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RiboNova, Inc. and MDI Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RiboNova, Inc., https://bouncewatch.com/company/ribonova-inc, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout